A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design. (October 2018)

• Record Type: Journal Article
• Authors: Morfouace, M.; Hewitt, S.M.; Salgado, R.; Hartmann, K.; Litiere, S.; Tejpar, S.; Golfinopoulos, V.; Lively, T.; Thurin, M.; Conley, B.; Lacombe, D.
• Is Part Of: Seminars in cancer biology. Volume 52(2018)Part 2
• Page Start: 158
• Page End: 165
• Publication Date: 2018-10
• Subjects: EORTC European Organization for Research and Treatment of Cancer -- NCI-MATCH National Cancer Institute- Molecular Analysis for Therapy Choice -- RECIST Response Evaluation Criteria In Solid Tumors -- SITC Society for ImmunoTherapy of Cancer -- SPECTA Screening cancer Patients for Efficient Clinical Trial Access; Immune therapies -- PD-L1 -- Biomarkers -- Clinical trial -- Tumor micro-environment; Cancer -- Periodicals; Neoplasms -- Periodicals; Review Literature; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.semcancer.2018.01.003
• Languages: English
• ISSNs: 1044-579X

Abstract

Abstract: Immuno-therapeutics aim to activate the body's own immune system against cancer and are one of the most promising cancer treatment strategies, but currently limited by a variable response rate. Biomarkers may help to distinguish those patients most likely to respond to therapy; they may also help guide clinical decision making for combination therapies, dosing schedules, and determining progression versus relapse. However, there is a need to confirm such biomarkers in preferably prospective clinical trials before they can be used in practice. Accordingly, it is essential that clinical trials for immuno-therapeutics incorporate biomarkers. Here, focusing on the specific setting of immune therapies, we discuss both the scientific and logistical hurdles to identifying potential biomarkers and testing them in clinical trials.